Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
H

ER+ Disease Highlights - mBC Series

By Dana-Farber Cancer Institute FEATURING Harold Burstein
By Dana-Farber Cancer Institute FEATURING Harold Burstein
142 views
February 15, 2024
Comments 0
Login to view comments. Click here to Login

Featured Video

13:36
Exelixis

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
2023-2024 EMBRACE MBC Virtual Forum Series
11:40

One of the Toughest Parts of Treatment: Managing "Scanxiety"

Dana-Farber Cancer Institute

J. Mosey

9 views
18:07

Concepts of Treatment, Progression, and Staging in mBC

Dana-Farber Cancer Institute

S. Sammons

39 views
34:39

Sexual Health and Sexual Recovery for Adults Living With mBC

Dana-Farber Cancer Institute

S. Bober

22 views
15:26

Antibody Drug Conjugates Highlights - mBC Series

Dana-Farber Cancer Institute

H. Burstein

317 views
04:04

Metastatic Disease Survivors - mBC Series

Dana-Farber Cancer Institute

H. Burstein

187 views
10:25

ER+ Disease Highlights - mBC Series

Dana-Farber Cancer Institute

H. Burstein

142 views
21:37

Standard Treatments for HR+/HER2- mBC in 2023

Dana-Farber Cancer Institute

S. Sammons

905 views
16:03

What’s New in Research for ER+ mBC

Dana-Farber Cancer Institute

A. Giordano

136 views
18:08

Current Treatment Options for Patients With HER2+ mBC

Dana-Farber Cancer Institute

N. Lin

295 views
15:37

HER2+ mBC: What’s Coming Up in Research?

Dana-Farber Cancer Institute

A. Waks

110 views
19:50

What's New in Treatment for TNBC

Dana-Farber Cancer Institute

M. Tesch

145 views
24:29

What's New in Research for mTNBC

Dana-Farber Cancer Institute

P. Tarantino

120 views
11:10

Antibody Drug Conjugates in Breast Cancer

Dana-Farber Cancer Institute

S. Tolaney

451 views
28:21

Recent Advances in mBC and Update on the EMBRACE Program

Dana-Farber Cancer Institute

N. Lin

92 views